Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Angiotech Pharmaceuticals has announced that the first New Zealand patient was treated with Cook Medical's Zilver PTX drug-eluting peripheral arterial disease stent in December 2007. A second patient was treated in February 2008.
Subscribe to our email newsletter
Under the terms of its 1997 license agreement with Cook, Angiotech is entitled to receive royalty payments upon the commercial sale of paclitaxel-eluting peripheral vascular stent products, including the Zilver PTX.
The Zilver PTX is currently undergoing multiple clinical trials in the US, Japan, and the EU to assess product safety and efficacy.
William Hunter, president and CEO of Angiotech, said: “Building on the success of our paclitaxel-eluting coronary stents, it is rewarding to see how our technology continues to be leveraged in other vascular indications. We hope that the Zilver PTX may provide a more long term treatment option for patients who suffer from peripheral arterial disease.”